ROBOSENSE
19.5.2023 13:01:28 CEST | Business Wire | Press release
RoboSense, a world-leading provider of smart LiDAR sensor systems, today announced it is now connected to the NVIDIA Omniverse ecosystem, using the development platform based on Universal Scene Description (USD) to accelerate the development, testing, and validation of its sensor technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005153/en/
RoboSense Joins NVIDIA Omniverse Ecosystem RoboSense's second-generation smart solid-state LiDAR model is integrated into NVIDIA DRIVE Sim, built on Omniverse, enabling physically based, high-fidelity sensor simulation. (Graphic: Business Wire)
RoboSense's second-generation smart solid-state LiDAR model is integrated into NVIDIA DRIVE Sim, built on Omniverse, enabling physically based, high-fidelity sensor simulation. With this integration, autonomous vehicle developers can directly access state-of-the-art LiDAR for development and testing. (Video: RoboSense LiDAR Model in NVIDIA DRIVE Sim)
DRIVE Sim is a reference application built on NVIDIA Omniverse, the connecting fabric between software ecosystems. It combines NVIDIA’s core technologies to deliver digital twin environments for developing and testing autonomous driving systems. With DRIVE Sim, developers can perform diverse and repeatable testing scenarios at a large scale, accelerating development and reducing cost.
As part of the Omniverse ecosystem, RoboSense will use the simulation platform to test and validate its new LiDAR systems - as well as provide ADAS developers access to highly accurate simulation models.
RoboSense's M-Series LiDAR is the world's first second-generation smart solid-state LiDAR to achieve mass production for automotive applications. It is currently the LiDAR with the most designated partnerships worldwide and has been implemented in a variety of vehicle models including the GAC Aion LX Plus, GAC Aion Hyper GT, SAIC IM LS7, SAIC IM L7, Lotus Eletre, XPeng G9, XPeng P7i, Great Wall WEY Mocha DHT-PHEV, Great Wall Motor WEY DHT-PHEV, and Chery Exeed STERRA ES, STERRA ET.
The M-Series LiDAR features a revolutionary two-dimensional MEMS scanning architecture, with unique “GAZE” function that can dynamically switch scanning modes and change scanning patterns based on the scenario, improving vehicle perception in complex environments. Based on RoboSense's leading patented technology, the M-Series LiDAR delivers point-cloud with outstanding quality, helping to address corner cases in autonomous driving perception.
By joining the NVIDIA Omniverse ecosystem, RoboSense enables developers to create complex road environments with high physical accuracy using its LiDAR model on the DRIVE Sim platform. The M series LiDAR model offers the flexibility to simulate its performance in beam control, custom scan patterns, and resolutions, which can then be used to generate synthetic datasets for training and validation of autonomous driving solutions.
Mark Qiu, co-founder and executive president of RoboSense, said, “The global automotive industry is undergoing a massive transformation, with ADAS and LiDAR markets continuing to gain traction. Leveraging the NVIDIA Omniverse ecosystem, RoboSense LiDAR technology and industry experience can be applied in a wider field, providing strong support for the development and verification of autonomous vehicles. RoboSense will work with NVIDIA to fully leverage the advantages of LiDAR technology, continuously improve the perception capabilities of autonomous vehicles, and achieve more efficient, safer, and smarter autonomous driving applications. We are committed to promoting the development of the global automotive and autonomous driving industries.”
Zvi Greenstein, a general manager at NVIDIA, said, “NVIDIA Omniverse is an open platform that includes leading LiDAR models from manufacturers worldwide. RoboSense's outstanding technical strength and customer base help strengthen our ecosystem and will accelerate the development and validation of autonomous vehicles while bringing more flexibility to developers.”
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom